Applications of teriparate on jaw osteonecrosis associated with the use of biphosphanates in implantodontics: an integrative review

• Autor(a) principal: Leitão, Karoline Bittencourt Mendes
• Data de Publicação: 2024
• Outros Autores: Nemetala, Renata Marques da Silva, Bugarin Júnior, João Geraldo
• Tipo de documento: Artigo
• Idioma: por
• Título da fonte: Revista JRG de Estudos Acadêmicos
• Texto Completo: http://revistajrg.com/index.php/jrg/article/view/1005
• topic: Teriparatida; Osteonecrose Associada a Bisfosfonatos da Mandíbula; Osteonecrose; Implantes Dentários; Teriparatide; Bisphosphonate-Associated Osteonecrosis of the Jaw; Osteonecrosis; Dental Implants

Dentistry is constantly concerned with the bone quality of its patients. This variable will determine the clinical success of surgical interventions, implant installation, and maintenance of teeth in the oral cavity. In this perspective, patients with osteoporosis are a population that requires greater attention. The current treatment for osteoporosis occurs through the use of bisphosphonates, however, its use is associated with cases of osteonecrosis of the jaws. Teriparatide is a medication that has been studied for the control of bone metabolism and demonstrates potential for dental use. Thus, this study sought to validate the use of teriparatide in the context of bisphosphonate-associated jaw osteonecrosis and its influence on Implantology. Teriparatide is a recombinant parathyroid hormone drug and has anabolic effects on bone metabolism, stimulating osteoblast differentiation and increasing osteocyte activity. Thus, bone anabolism can be thought of as a way to recover clinical conditions with significant losses of mineralized tissue, assisting in the patient's rehabilitation process. In dentistry, the use of teriparatide is associated with higher and better levels of implant osseointegration and positive effects on periodontal tissues. Its use can also be enhanced by supplementation of vitamin D and calcium. In light of these findings, the use of teriparatide may be an alternative for osteoporosis control in the face of bisphosphonates during the period when dental implant installation or bone surgeries in the head and neck region are planned, reducing the risks of necrosis in the area. However, it is important to emphasize that clinical studies still lack more robust experimental designs and larger samples so that teriparatide is truly a valid and safe choice for patients.